{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:49:16Z","timestamp":1773373756488,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00415-021-10951-6","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T21:19:28Z","timestamp":1641331168000},"page":"2275-2285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6267","authenticated-orcid":false,"given":"Luca","family":"Prosperini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalom","family":"Haggiag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Galgani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"10130","key":"10951_CR1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018) Multiple sclerosis. Lancet 391(10130):1622\u20131636","journal-title":"Lancet"},{"issue":"2","key":"10951_CR2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1212\/WNL.0b013e31829a3388","volume":"81","author":"A Scalfari","year":"2013","unstructured":"Scalfari A, Knappertz V, Cutter G et al (2013) Mortality in patients with multiple sclerosis. Neurology 81(2):184\u2013192","journal-title":"Neurology"},{"issue":"2","key":"10951_CR3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1468-1331.2007.02019.x","volume":"15","author":"P Ragonese","year":"2008","unstructured":"Ragonese P, Aridon P, Salemi G, D\u2019Amelio M, Savettieri G (2008) Mortality in multiple sclerosis: a review. Eur J Neurol 15(2):123\u2013127","journal-title":"Eur J Neurol"},{"issue":"11","key":"10951_CR4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","volume":"17","author":"E Grebenciucova","year":"2017","unstructured":"Grebenciucova E, Pruitt A (2017) Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep 17(11):88","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"10951_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","volume":"17","author":"E Grebenciucova","year":"2017","unstructured":"Grebenciucova E, Berger JR (2017) Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis. Curr Neurol Neurosci Rep 17(8):61","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"10951_CR6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41582-020-0368-9","volume":"16","author":"H-P Hartung","year":"2020","unstructured":"Hartung H-P, Aktas O (2020) COVID-19 and management of neuroimmunological disorders. Nat Rev Neurol 16(7):347\u2013348","journal-title":"Nat Rev Neurol"},{"key":"10951_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10803-3","author":"L Prosperini","year":"2021","unstructured":"Prosperini L, Tortorella C, Haggiag S et al (2021) Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. J Neurol. https:\/\/doi.org\/10.1007\/s00415-021-10803-3","journal-title":"J Neurol"},{"issue":"1","key":"10951_CR8","doi-asserted-by":"publisher","first-page":"e1105","DOI":"10.1212\/NXI.0000000000001105","volume":"9","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Schiavetti I, Carmisciano L et al (2021) COVID-19 severity in multiple sclerosis: putting data into context. Neurol Neuroimmunol Neuroinflamm 9(1):e1105. https:\/\/doi.org\/10.1212\/NXI.0000000000001105","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10951_CR9","doi-asserted-by":"crossref","first-page":"e1001","DOI":"10.1212\/NXI.0000000000001001","volume":"8","author":"M Barzegar","year":"2021","unstructured":"Barzegar M, Mirmosayyeb O, Gajarzadeh M et al (2021) COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflammation 8(4):e1001","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"11","key":"10951_CR10","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1111\/ene.14990","volume":"28","author":"I Moreno-Torres","year":"2021","unstructured":"Moreno-Torres I, Meca Lallana V et al (2021) Risk and outcomes of COVID-19 in patients with multiple sclerosis. Eur J Neurol 28(11):3712\u20133721","journal-title":"Eur J Neurol"},{"key":"10951_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012753","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, Brouwer ED, Kalincik T et al (2021) Associations of DMT therapies with COVID-19 severity in multiple sclerosis. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000012753","journal-title":"Neurology"},{"issue":"3","key":"10951_CR12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","volume":"35","author":"AT Reder","year":"2021","unstructured":"Reder AT, Centonze D, Naylor ML et al (2021) COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs 35(3):317\u2013330","journal-title":"CNS Drugs"},{"issue":"3","key":"10951_CR13","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med Peer-Rev Indep Open-Access J 3(3):e123-130","journal-title":"Open Med Peer-Rev Indep Open-Access J"},{"key":"10951_CR14","first-page":"1057","volume":"192","author":"D O\u2019Sullivan","year":"2013","unstructured":"O\u2019Sullivan D, Wilk S, Michalowski W, Farion K (2013) Using PICO to align medical evidence with MDs decision making models. Stud Health Technol Inform 192:1057","journal-title":"Stud Health Technol Inform"},{"key":"10951_CR15","doi-asserted-by":"crossref","unstructured":"Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2(2):MR000033.","DOI":"10.1002\/14651858.MR000033.pub3"},{"issue":"11","key":"10951_CR16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452","journal-title":"Neurology"},{"issue":"9","key":"10951_CR17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605","journal-title":"Eur J Epidemiol"},{"key":"10951_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.178","author":"L Lin","year":"2020","unstructured":"Lin L, Xu C (2020) Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives. Rep Health Sci. https:\/\/doi.org\/10.1002\/hsr2.178","journal-title":"Rep Health Sci"},{"issue":"9","key":"10951_CR19","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/sim.2688","volume":"26","author":"K Sidik","year":"2007","unstructured":"Sidik K, Jonkman JN (2007) A comparison of heterogeneity variance estimators in combining results of studies. Stat Med 26(9):1964\u20131981","journal-title":"Stat Med"},{"key":"10951_CR20","doi-asserted-by":"crossref","first-page":"102886","DOI":"10.1016\/j.msard.2021.102886","volume":"51","author":"R Alonso","year":"2021","unstructured":"Alonso R, Silva B, Garcea O et al (2021) COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America. Mult Scler Relat Disord 51:102886","journal-title":"Mult Scler Relat Disord"},{"key":"10951_CR21","doi-asserted-by":"crossref","first-page":"103004","DOI":"10.1016\/j.msard.2021.103004","volume":"52","author":"F Alshamrani","year":"2021","unstructured":"Alshamrani F, Alnajashi H, AlJumah M et al (2021) Registry of patients with multiple sclerosis an COVID-19 infection in Saudi Arabia. Mult Scler Relat Disord 52:103004","journal-title":"Mult Scler Relat Disord"},{"key":"10951_CR22","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1212\/NXI.0000000000001024","volume":"8","author":"G Arrambide","year":"2021","unstructured":"Arrambide G, Llaneza-Gonz\u00e1lez M\u00c1, Costa-Frossard Fran\u00e7a L et al (2021) SARS-CoV-2 infection in multiple sclerosis: results of the Spanish Neurology Society Registry. Neurol Neuroimmunol Neuroinflam 8:e1024","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"10951_CR23","doi-asserted-by":"crossref","first-page":"102276","DOI":"10.1016\/j.msard.2020.102276","volume":"45","author":"M Barzegar","year":"2020","unstructured":"Barzegar M, Mirmosayyeb O, Ghajarzadeh M et al (2020) Characteristics of COVID-19 disease in multiple sclerosis patients. Mult Scler Relat Disord 45:102276","journal-title":"Mult Scler Relat Disord"},{"key":"10951_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.17.20214429","author":"M Bayat","year":"2020","unstructured":"Bayat M, Fayyazpoor A, Haghighi AB et al (2020) SARS-CoV-2 infection among patients with multiple sclerosis, a cross-sectional study. MedRxiv. https:\/\/doi.org\/10.1101\/2020.10.17.20214429","journal-title":"MedRxiv"},{"key":"10951_CR25","doi-asserted-by":"publisher","unstructured":"Brum DG et al. Neuroimmunology Brazilian Study Group Focused on COVID-19 and MS (2021) Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis. Mult Scler.https:\/\/doi.org\/10.1177\/1352458520978354.","DOI":"10.1177\/1352458520978354"},{"key":"10951_CR26","doi-asserted-by":"crossref","first-page":"e0255316","DOI":"10.1371\/journal.pone.0255316","volume":"16","author":"G Bsteh","year":"2021","unstructured":"Bsteh G, Assar H, Hegen H et al (2021) COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: insights from a nation-wide Austrian registry. PLoS ONE 16:e0255316","journal-title":"PLoS ONE"},{"key":"10951_CR27","doi-asserted-by":"crossref","first-page":"117147","DOI":"10.1016\/j.jns.2020.117147","volume":"418","author":"F Chaudhry","year":"2020","unstructured":"Chaudhry F, Bulka H, Rathnam AS et al (2020) COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci 418:117147","journal-title":"J Neurol Sci"},{"key":"10951_CR28","doi-asserted-by":"crossref","first-page":"102392","DOI":"10.1016\/j.msard.2020.102392","volume":"45","author":"E Ciampi","year":"2020","unstructured":"Ciampi E, Uribe-San-Mart\u00edn R, Soler B et al (2020) COVID-19 in MS and NMOSD: a multicentric online national survey in Chile. Mult Scler Relat Disord 45:102392","journal-title":"Mult Scler Relat Disord"},{"key":"10951_CR29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5603\/PJNNS.a2021.0031","volume":"55","author":"A Czarnowska","year":"2021","unstructured":"Czarnowska A, Brola W, Zajkowska O et al (2021) Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies\u2014the Polish experience. Neurol Neurochir Pol 55:11","journal-title":"Neurol Neurochir Pol"},{"key":"10951_CR30","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1177\/1352458520942198","volume":"26","author":"FC Loonstra","year":"2020","unstructured":"Loonstra FC, Hoitsma E, van Kempen ZL et al (2020) COVID-19 in multiple sclerosis: the Dutch experience. Mult Scler 26:1256\u20131260","journal-title":"Mult Scler"},{"issue":"9","key":"10951_CR31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","volume":"77","author":"C Louapre","year":"2020","unstructured":"Louapre C, Collongues N, Stankoff B et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 77(9):1079\u20131088","journal-title":"JAMA Neurol"},{"key":"10951_CR32","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","volume":"7","author":"E Parrotta","year":"2020","unstructured":"Parrotta E, Kister I, Charvet L et al (2020) COVID-19 outcomes in MS: observational study of early experience from NYU multiple sclerosis comprehensive care center. Neurol Neuroimmunol Neuroinflam 7:e835","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"10951_CR33","doi-asserted-by":"crossref","unstructured":"Sahraian MA, Azimi A, Navardi S, et al (2020) Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 46:102472.","DOI":"10.1016\/j.msard.2020.102472"},{"issue":"6","key":"10951_CR34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","volume":"78","author":"A Salter","year":"2021","unstructured":"Salter A, Fox RJ, Newsome SD et al (2021) Outcomes and risk factors associated with SARS-CoV-2 infection in a north American registry of patients with multiple sclerosis. JAMA Neurol 78(6):699\u2013708","journal-title":"JAMA Neurol"},{"key":"10951_CR35","doi-asserted-by":"crossref","first-page":"102968","DOI":"10.1016\/j.msard.2021.102968","volume":"52","author":"S Sen","year":"2021","unstructured":"Sen S, Karabudak R, Schiavetti I et al (2021) The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals? Mult Scler Relat Disord 52:102968","journal-title":"Mult Scler Relat Disord"},{"key":"10951_CR36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, De Rossi N, Schiavetti I et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89:780\u2013789","journal-title":"Ann Neurol"},{"key":"10951_CR37","doi-asserted-by":"crossref","first-page":"103104","DOI":"10.1016\/j.msard.2021.103104","volume":"54","author":"D Stastna","year":"2021","unstructured":"Stastna D, Menkyova I, Drahota J et al (2021) Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: a pandemic year in Czechia. Mult Scler Relat Disord 54:103104","journal-title":"Mult Scler Relat Disord"},{"key":"10951_CR38","doi-asserted-by":"crossref","unstructured":"Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. Available at: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2763667 [Accessed August 26, 2021].","DOI":"10.1001\/jama.2020.4683"},{"issue":"8","key":"10951_CR39","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51408","volume":"8","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Salvetti M, Labauge P et al (2021) DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol 8(8):1738\u20131744","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"10951_CR40","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/ene.12130","volume":"20","author":"S Montgomery","year":"2013","unstructured":"Montgomery S, Hillert J, Bahmanyar S (2013) Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol 20(8):1153\u20131160","journal-title":"Eur J Neurol"},{"issue":"5","key":"10951_CR41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7224\/1537-2073.2014-035","volume":"17","author":"RE Nelson","year":"2015","unstructured":"Nelson RE, Xie Y, DuVall SL et al (2015) Multiple sclerosis and risk of infection-related hospitalization and death in US veterans. Int J MS Care 17(5):221\u2013230","journal-title":"Int J MS Care"},{"issue":"6","key":"10951_CR42","doi-asserted-by":"crossref","first-page":"e001972","DOI":"10.1136\/bmjopen-2012-001972","volume":"2","author":"DS Goodin","year":"2012","unstructured":"Goodin DS, Ebers GC, Cutter G et al (2012) Cause of death in MS: long-term follow-up of a randomised cohort, 21\u2005years after the start of the pivotal IFN\u03b2-1b study. BMJ Open 2(6):e001972","journal-title":"BMJ Open"},{"issue":"8","key":"10951_CR43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","volume":"10","author":"KA Sacco","year":"2018","unstructured":"Sacco KA, Abraham RS (2018) Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy 10(8):713\u2013728","journal-title":"Immunotherapy"},{"issue":"2","key":"10951_CR44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77(2):184\u2013191","journal-title":"JAMA Neurol"},{"issue":"3","key":"10951_CR45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458520952311","volume":"27","author":"L Moiola","year":"2021","unstructured":"Moiola L, Barcella V, Benatti S et al (2021) The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement. Mult Scler 27(3):331\u2013346","journal-title":"Mult Scler"},{"issue":"6","key":"10951_CR46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"WHO Solidarity Trial Consortium, Pan H, Peto R et al (2021) Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results. N Engl J Med 384(6):497\u2013511","journal-title":"N Engl J Med"},{"key":"10951_CR47","doi-asserted-by":"crossref","unstructured":"Zhang Q, Bastard P, Liu Z, et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370(6515):eabd4570.","DOI":"10.1126\/science.abd4570"},{"key":"10951_CR48","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3389\/fimmu.2020.01459","volume":"11","author":"M Severa","year":"2020","unstructured":"Severa M, Farina C, Salvetti M, Coccia EM (2020) Three decades of interferon-\u03b2 in multiple sclerosis: can we repurpose this information for the management of SARS-CoV2 infection? Front Immunol 11:1459","journal-title":"Front Immunol"},{"issue":"10","key":"10951_CR49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","volume":"89","author":"JMA Wijnands","year":"2018","unstructured":"Wijnands JMA, Zhu F, Kingwell E et al (2018) Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry 89(10):1050\u20131056","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10951_CR50","doi-asserted-by":"crossref","first-page":"e1003678","DOI":"10.1371\/journal.ppat.1003678","volume":"9","author":"M Lucas-Hourani","year":"2013","unstructured":"Lucas-Hourani M, Dauzonne D, Jorda P et al (2013) Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 9(10):e1003678","journal-title":"PLoS Pathog"},{"issue":"2","key":"10951_CR51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ebmental-2019-300129","volume":"23","author":"S Metelli","year":"2020","unstructured":"Metelli S, Chaimani A (2020) Challenges in meta-analyses with observational studies. Evid Based Ment Health 23(2):83\u201387","journal-title":"Evid Based Ment Health"},{"key":"10951_CR52","doi-asserted-by":"crossref","unstructured":"Sedgwick P (2011) The ecological fallacy. BMJ. Available at: https:\/\/www.bmj.com\/content\/343\/bmj.d4670 [Accessed May 3, 2020].","DOI":"10.1136\/bmj.d4670"},{"key":"10951_CR53","doi-asserted-by":"crossref","first-page":"175628642110128","DOI":"10.1177\/17562864211012835","volume":"14","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S et al (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14:17562864211012836","journal-title":"Ther Adv Neurol Disord"},{"key":"10951_CR54","doi-asserted-by":"crossref","unstructured":"Tortorella C, Aiello A, Gasperini C, et al (2021) Humoral and T-cell specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology [Accepted for publication].","DOI":"10.1212\/WNL.0000000000013108"},{"issue":"11","key":"10951_CR55","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1007\/s00415-021-10545-2","volume":"268","author":"D Centonze","year":"2021","unstructured":"Centonze D, Rocca MA, Gasperini C et al (2021) Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 268(11):3961\u20133968","journal-title":"J Neurol"},{"key":"10951_CR56","doi-asserted-by":"crossref","first-page":"102174","DOI":"10.1016\/j.msard.2020.102174","volume":"43","author":"D Baker","year":"2020","unstructured":"Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G (2020) The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat. Disord. 43:102174","journal-title":"Mult Scler Relat. Disord."}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10951-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T14:29:30Z","timestamp":1650551370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10951-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10951"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10951-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"18 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to report relevant to the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}